Brief Summary
The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).
Intervention / Treatment
- Biological: Luspatercept
- Biological: Epoetin Alfa
Inclusion Criteria
- Participant has documented diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of MDS according to World Health Organization (WHO) 2016 that meet IPSS-R classification of very low, low, or intermediate-risk disease, (intermediate-risk of ≤ 3.5 IPSS-R score) confirmed via bone marrowsoft, spongy tissue found in bones that makes blood cells aspirateto draw out fluid or tissue from the body, often with a syringe and:.i) < 5% blasts in bone marrow and < 1% blasts in peripheral bloodthe red bodily fluid that transports oxygen and other nutrients around the body.
- Participant is not transfusion dependent (NTD) based on IWG2018 criteria.
- Participant is erythropoiesis-stimulating agent naive. Participants may be randomized at the investigator’s discretion if the participant received no more than 2 prior doses of epoetin alfa, epoetin alfa biosimilar, or darbepoetin alfa, with the last dosethe amount of medication taken at least 8 weeks prior to randomization.
- Participant has a baseline endogenous serum erythropoietin (sEPO) level of ≤ 500 U/L.
- Participant has symptoms of anemia:.i) Participant records a severity score of “moderate” or greater on at least 1 PGI-S item of fatiguea state of extreme tiredness or exhaustion, can be physical or mental, weakness, shortness of breath, or dizziness performed during the screeningtesting for cancer or conditions that can lead to cancer before symptoms appear, also known as cancer screening period.
- Participant has a baseline Hb concentration prior to randomization of ≤ 9.5 g/dL. The baseline Hb will be calculated using the mean of the two lowest available Hb measurements within 16 weeks prior to randomization and must include at least one central lab Hb reading done within the screening period (no more than 35 days before randomization). The two Hb measurements must have been performed at least seven days apart. Hb levels less than 21 days following RBC transfusion should not be used. Split samples for local assessments are not required.